Full Breakdown
Bayer AG Reports Significant Q4 Loss Amid Litigation Costs and Weak Sales
3/4/2026, 9:04:28 PM
Financial Overview and Q4 Performance
Bayer AG, the German pharmaceutical and life sciences company, reported a substantial net loss of €3.76 billion in the fourth quarter of 2023, a significant increase from a loss of €335 million during the same period last year. The loss per share was recorded at €3.82, compared to €0.34 in the previous year. The company's adjusted earnings before interest and taxes (EBIT) fell by 20.2% to €682 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) decreased by 16.2% to €1.97 billion. Sales also declined by 2.5% to €11.44 billion, primarily due to weak performance in the pharmaceuticals and consumer health sectors, despite a slight growth in crop science.
Litigation Costs and Settlement Agreement
Bayer's financial results were heavily impacted by high special charges related to ongoing litigation, particularly concerning Roundup (glyphosate) claims. In mid-February, Bayer's subsidiary, Monsanto, announced a proposed nationwide class settlement aimed at resolving claims alleging non-Hodgkin lymphoma injuries. This settlement includes a commitment from Monsanto to make capped annual payments totaling up to €7.25 billion over 21 years, pending court approval. Bayer anticipates that total litigation-related payouts could reach approximately €5 billion by 2026.
Future Outlook for 2026
Looking ahead, Bayer has issued a cautious outlook for fiscal 2026, projecting core earnings per share between €4.30 and €4.80, adjusted EBITDA of €9.6 billion to €10.1 billion, and sales ranging from €45 billion to €47 billion. This forecast indicates a potential year-on-year change of 0% to +3% on a currency- and portfolio-adjusted basis. The company’s new methodology for calculating core earnings per share reflects a shift from the previous approach, which reported €4.91 per share for 2025.
Official Statements & Responses
Bayer's management emphasized that the company's earnings and outlook are significantly influenced by the class settlement agreement related to Roundup claims. The company aims to stabilize its financial performance while addressing ongoing litigation challenges. The upcoming Annual Stockholders' Meeting on April 24, 2026, will include proposals for the election of two stockholder representatives to the Supervisory Board, Marcel Smits and Alfred Stern.
Criticism & Opposition
Critics have raised concerns regarding Bayer's handling of litigation and its financial strategies, particularly the long-term implications of the Roundup settlement. Some stakeholders argue that the company's focus on litigation costs detracts from its core business operations and growth potential.
Verbatim Quotes
“The company noted that its earnings and outlook reflect class settlement agreement to resolve current and future Roundup (glyphosate) claims.” — Bayer AG Management
“The total litigation related payouts is expected to reach approximately 5 billion euros in 2026.” — Bayer AG Management
This comprehensive financial report highlights Bayer AG's significant challenges in the fourth quarter of 2023, driven by litigation costs and declining sales, while outlining a cautious yet hopeful outlook for the future.
